doxorubicin liposome

DRUG2 trials

Sponsors

Sun Yat-sen University, Jiangsu Simcere Pharmaceutical Co., Ltd.

Conditions

Breast CancerNeoadjuvant ChemotherapyOvarian Cancer

Phase 2

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

Active, not recruitingNCT04172259

Sun Yat-sen UniversityBreast Cancer, Neoadjuvant Chemotherapy

Start: 2019-01-10End: 2026-09-30Target: 156Updated: 2023-10-16

Phase 3

A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer

CompletedNCT04908787

Jiangsu Simcere Pharmaceutical Co., Ltd.Ovarian Cancer

Start: 2021-06-11End: 2024-10-11Updated: 2025-09-11

Related Papers

Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial.

2026-01-09

Final analysis of SCORES, a phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer.

Journal of Clinical Oncology2025-05-28

A phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer (SCORES).

Journal of Clinical Oncology2024-06-051 citations

Neoadjuvant pegylated liposomal doxorubicin-containing chemotherapy in combination with trastuzumab and pertuzumab in patients with HER2-positive early breast cancer: A randomized phase II study (METIS).

Journal of Clinical Oncology2024-06-011 citations